Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
S&P 500 Gains & Losses Today: Amazon Stock Drops; Monolithic Power Surges
Key Takeaways The S&P 500 dropped 1.6% on Friday, Aug. 1, 2025, after the July jobs report revealed an unanticipated level of pressure on the U.S. labor market. Shares of Eastman Chemical plummeted after the maker of specialty chemicals reported year-over-year sales and profit declines. Tech giant Amazon's stock also dropped Friday. Monolithic Power released strong quarterly results, with growth across numerous end markets, and shares of the power management chipmaker U.S. equities indexes tumbled on the final day of the trading week and the first day of the new month after the latest Bureau of Labor Statistics report showed a lower-than-expected pace of hiring in July. The data also showed an uptick in the unemployment rate, along with sharp downward revisions to jobs numbers from May and June. The unexpectedly weak numbers suggest that pressure on the labor market could be more intense than previously believed. That could encourage the Federal Reserve to lower interest rates at its upcoming meetings. The S&P 500 fell 1.6% on Friday, suffering its fourth straight down day as the benchmark index extended its retreat from the record closing high set at the beginning of the week. The Dow ended 1.2% lower, while the Nasdaq dropped 2.2%. Read Investopedia's full daily markets roundup here. Shares of Eastman Chemical (EMN) plunged 19%, experiencing the heaviest decline of any S&P 500 stock. The provider of specialty chemicals reported second-quarter sales and profits that declined year-over and fell short of analysts' expectations. Coinbase Global (COIN), operator of the largest U.S. cryptocurrency exchange, posted second-quarter revenue and adjusted earnings before interest, taxes, depreciation, and amortization that fell short of estimates. Transactions revenue as well as subscriptions and services revenue fell from the previous quarter. Coinbase stock, which fell about 17% on Friday. Although Amazon (AMZN) topped revenue and net income estimates with its second-quarter results, shares of the e-commerce giant slipped 8.3%. Jefferies analysts said growth from the Amazon Web Services cloud computing business was disappointing compared with blowout growth figures from competitor Microsoft (MSFT) and its Azure cloud platform. Other research firms suggested that the pullback in Amazon stock could represent a buying opportunity. The top daily performance in the S&P 500 belonged to shares of Monolithic Power Systems (MPWR), which surged more than 10%. The power management chipmaker reported sales and adjusted profits for the second quarter that surpassed analysts' expectations, boosted by a strong performance in its storage and computing, automotive, and communication markets. Shares of Align Technology (ALGN) advanced 5.8% on Friday, clawing back a portion of the losses posted in the prior session. In quarterly results released Wednesday afternoon, the maker of transparent teeth straighteners and other technological dentistry products reported lower-than-expected sales and profits and announced restructuring measures including workforce cuts. First Solar (FSLR) reported stronger-than-expected sales and profits for the second quarter, and shares of the panel manufacturer jumped 5.3%. The company also increased its full-year sales forecast, and CEO Mark Widmar said shifts in trade policy have strengthened First Solar's position in the industry. Read the original article on Investopedia Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
32 minutes ago
- Yahoo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
